← Back to Clinical Trials
Recruiting NCT05902195

NCT05902195 Improving Work Ability of Young Adults With Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05902195
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2023-01-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Personal Resource Building and Inclusive Volunteering Intervention (PVI)Usual care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project will investigate effects of a novel theory-driven 6-week virtual Personal Resource Building and Inclusive Volunteering Intervention (PVI) on young stroke survivors' work ability, self-efficacy and psychosocial outcomes. It is hypothesised that participants in the intervention group, compared with the control group, will demonstrate the outcomes below at immediately and 3 months post-intervention with respect to baseline: 1) Significant improvement in work ability (primary outcome), 2) Significant improvements in self-efficacy, health-related quality of life (HRQoL), emotional well-being and social skills (secondary outcomes). Eligible participants will be randomly assigned to receive usual care or PVI with usual care and the control group participants will receive usual stroke care services.

Eligibility Criteria

Inclusion Criteria: * 18-64 years old, * been clinically diagnosed with a first-ever or recurrent ischaemic or haemorrhagic stroke, * living at home, * Montreal Cognitive Assessment score \>2nd percentile, * a Modified Rankin Scale of 4 or below (moderately severe disability), * able to communicate in Cantonese and read Traditional Chinese, * a regular paid employment at the time of stroke, * been unemployed for at least 3 months at the time of recruitment. Exclusion Criteria: * have been diagnosed with transient ischaemic attack, * have experienced cerebrovascular events due to tumours, * have been diagnosed with a mental condition such as depression, schizophrenia or bipolar disorder, * demonstrate incomprehensible speech or difficulty in comprehending conversations, or * have or are receiving vocational programmes.

Contact & Investigator

Central Contact

Suzanne Lo

✉ suzannelo@cuhk.edu.hk

📞 852 3943 4485

Principal Investigator

Suzanne Lo

PRINCIPAL INVESTIGATOR

Chinese University of Hong Kong

Frequently Asked Questions

Who can join the NCT05902195 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05902195 currently recruiting?

Yes, NCT05902195 is actively recruiting participants. Contact the research team at suzannelo@cuhk.edu.hk for enrollment information.

Where is the NCT05902195 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT05902195 clinical trial?

NCT05902195 is sponsored by Chinese University of Hong Kong. The principal investigator is Suzanne Lo at Chinese University of Hong Kong. The trial plans to enroll 160 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology